CLINICAL EXPERIENCE WITH IMMUNOGLOBULIN SIGARDIS AS REPLACEMENT THERAPY IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY
- 作者: Drobyshevskaya V.1,2, Krivtsun O.2
-
隶属关系:
- St. Petersburg Pasteur Research Institute of Epidemiology and Microbiology
- First St. Petersburg State I. Pavlov Medical University
- 期: 卷 22, 编号 4 (2019)
- 页面: 1460-1462
- 栏目: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/1028-7221/article/view/119533
- DOI: https://doi.org/10.31857/S102872210007057-7
- ID: 119533
如何引用文章
全文:
详细
Practically valuable information on the use of the IMMUNOGLOBULIN SIGARDIS drug as a pathogenetic treatment of patients with a defect in antibody production. The article presents data from the study of the drug for compliance with the criteria, presented to the Intravenous immunoglobulin by the World Health Organization, the comparative characteristics of the antibodies that make up the drug according to the spectra and titers with the Russian, the data on the clinical and laboratory efficacy of the drug.
作者简介
V. Drobyshevskaya
St. Petersburg Pasteur Research Institute of Epidemiology and Microbiology;First St. Petersburg State I. Pavlov Medical University
编辑信件的主要联系方式.
Email: v.g.drobyshevskaia@yandex.ru
аllergist-immunologist, Medical Center;
high school teacher, Department of Immunology,
St. Petersburg
俄罗斯联邦O. Krivtsun
First St. Petersburg State I. Pavlov Medical University
Email: fake@neicon.ru
student,
St. Petersburg
俄罗斯联邦参考
- Латышева Е. А. «Первичные иммунодефициты у взрослых. Особенности диагностики и лечения.», Москва, 2018 г.
- Федеральные клинические рекомендации по диагностике и лечению больных первичными иммунодефицитами с нарушением гуморального звена. РААКИ, Москва 2014 год.
